192 related articles for article (PubMed ID: 19195335)
1. Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once daily.
van der Flier M; Verweel G; van der Knaap LC; van Jaarsveld P; Driessen GJ; van der Lee M; Hartwig NG; Burger DM
Antivir Ther; 2008; 13(8):1087-90. PubMed ID: 19195335
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children.
la Porte C; van Heeswijk R; Mitchell CD; Zhang G; Parker J; Rongkavilit C
Antivir Ther; 2009; 14(4):603-6. PubMed ID: 19578247
[TBL] [Abstract][Full Text] [Related]
3. Lopinavir/ritonavir exposure in treatment-naive HIV-infected children following twice or once daily administration.
Rosso R; Di Biagio A; Dentone C; Gattinara GC; Martino AM; Viganò A; Merlo M; Giaquinto C; Rampon O; Bassetti M; Gatti G; Viscoli C
J Antimicrob Chemother; 2006 Jun; 57(6):1168-71. PubMed ID: 16606636
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
van der Lee M; Verweel G; de Groot R; Burger D
Antivir Ther; 2006; 11(4):439-45. PubMed ID: 16856617
[TBL] [Abstract][Full Text] [Related]
5. Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.
Verweel G; Burger DM; Sheehan NL; Bergshoeff AS; Warris A; van der Knaap LC; Driessen G; de Groot R; Hartwig NG
Antivir Ther; 2007; 12(4):453-8. PubMed ID: 17668553
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Puthanakit T; van der Lugt J; Bunupuradah T; Ananworanich J; Gorowara M; Phasomsap C; Jupimai T; Boonrak P; Pancharoen C; Burger D; Ruxrungtham K
J Antimicrob Chemother; 2009 Nov; 64(5):1080-6. PubMed ID: 19729375
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentrations of generic lopinavir/ritonavir in HIV type-1-infected individuals.
van der Lugt J; Lange J; Avihingsanon A; Ananworanich J; Sealoo S; Burger D; Gorowara M; Phanuphak P; Ruxrungtham K
Antivir Ther; 2009; 14(7):1001-4. PubMed ID: 19918104
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation.
Boffito M; Else L; Back D; Taylor J; Khoo S; Sousa M; Pozniak A; Gazzard B; Moyle G
Antivir Ther; 2008; 13(7):901-7. PubMed ID: 19043924
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients.
van der Lee M; Sankatsing R; Schippers E; Vogel M; Fätkenheuer G; van der Ven A; Kroon F; Rockstroh J; Wyen C; Bäumer A; de Groot E; Koopmans P; Stroes E; Reiss P; Burger D
Antivir Ther; 2007; 12(7):1127-32. PubMed ID: 18018771
[TBL] [Abstract][Full Text] [Related]
10. Association of total bilirubin with indinavir and lopinavir plasma concentrations in HIV-infected patients receiving three different double-boosted dosing regimens.
Dicenzo R; Luque A; Larppanichpoonphol P; Reichman R
J Antimicrob Chemother; 2006 Aug; 58(2):393-400. PubMed ID: 16760191
[TBL] [Abstract][Full Text] [Related]
11. Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults.
DiCenzo R; DiFrancesco R; Cruttenden K; Donnelly J; Schifitto G
Ann Pharmacother; 2009 Dec; 43(12):1972-7. PubMed ID: 19934383
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of two generic co-formulations of lopinavir/ritonavir for HIV-infected children: a pilot study of paediatric Lopimune versus the branded product in healthy adult volunteers.
de Kanter CT; Colbers EP; Fillekes Q; Hoitsma A; Burger DM
J Antimicrob Chemother; 2010 Mar; 65(3):538-42. PubMed ID: 20056686
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and short-term efficacy of a double-boosted protease inhibitor regimen in treatment-naive HIV-1-infected adults.
van der Lugt J; Autar RS; Ubolyam S; Garcia EF; Sankote J; Avihingsanon A; Chuenyam T; Cooper DA; Lange J; Phanuphak P; Wit F; Ruxrungtham K; Burger D;
J Antimicrob Chemother; 2008 May; 61(5):1145-53. PubMed ID: 18285316
[TBL] [Abstract][Full Text] [Related]
14. Once- versus twice-daily lopinavir/ritonavir tablets in virologically suppressed, HIV-infected, treatment-experienced children: comparative pharmacokinetics and virological outcome after switching to once-daily lopinavir/ritonavir.
Chokephaibulkit K; Nuntarukchaikul M; Phongsamart W; Wittawatmongkol O; Lapphra K; Vanprapar N; Cressey TR
J Antimicrob Chemother; 2012 Dec; 67(12):2927-31. PubMed ID: 22923483
[TBL] [Abstract][Full Text] [Related]
15. Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients.
van Heeswijk RP; Bourbeau M; Seguin I; Giguere P; Garber GE; Cameron DW
Br J Clin Pharmacol; 2005 Apr; 59(4):398-404. PubMed ID: 15801934
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.
von Hentig N; Müller A; Rottmann C; Lutz T; Klauke S; Kurowski M; Staszewski S; Harder S
Eur J Med Res; 2006 Jun; 11(6):236-44. PubMed ID: 16820336
[TBL] [Abstract][Full Text] [Related]
17. Low dose lopinavir/ritonavir tablet achieves adequate pharmacokinetic parameters in HIV-infected Thai adolescents.
Klinklom A; Puthanakit T; Gorowara M; Phasomsap C; Kerr S; Sriheara C; Ananworanich J; Burger D; Ruxrungtham K; Pancharoen C
Antivir Ther; 2012; 17(2):283-9. PubMed ID: 22293065
[TBL] [Abstract][Full Text] [Related]
18. Comment on: Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Neely MN; Rakhmanina NY
J Antimicrob Chemother; 2010 Apr; 65(4):808-9; author reply 809-10. PubMed ID: 20086000
[No Abstract] [Full Text] [Related]
19. A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients.
Bouillon-Pichault M; Jullien V; Piketty C; Viard JP; Morini JP; Chhun S; Krivine A; Salmon D; Dupin N; Weiss L; Lortholary O; Pons G; Launay O; Treluyer JM
Antivir Ther; 2009; 14(7):923-9. PubMed ID: 19918096
[TBL] [Abstract][Full Text] [Related]
20. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir.
Klein CE; Chiu YL; Cai Y; Beck K; King KR; Causemaker SJ; Doan T; Esslinger HU; Podsadecki TJ; Hanna GJ
J Clin Pharmacol; 2008 May; 48(5):553-62. PubMed ID: 18440920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
